Meta-analysis on the effectiveness of SGLT2 inhibitors in heart failure

Abstract Funding Acknowledgements Type of funding sources: None. Aims We aimed to carry out a meta-analysis on the effectiveness sodium-glucose co transporter 2 (SGLT2) inhibitors in heart failure patients (HF) with preserved and reduced ejection fraction. Methods results From their inception till September 2022, MEDLINE, Scopus, Cochrane CENTRAL, ClinicalTrials.gov were searched for placebo-controlled randomized controlled trials SGLT2 inhibitors. Randomized studies chosen if they included HF reported at least one predetermined outcomes. A random effects model was used pool hazard ratios (HRs) or risk together appropriate 95% confidence intervals. There fourteen total, 42409 participating (N = 21678 inhibitor arms N 20731 placebo arms). In overall cohort, significantly composite first hospitalization cardiovascular death [HR: 0.75 (0.71–0.79); P <0.001; I2 0%]. Also resulted significant reduction total hospitalizations 0.70 (0.66–0.75); < 0.001; 0%] occurrence 0.86 (0.81–0.92); 43%]. Sub-group analysis conducted based status baseline, fraction, diabetes gender. all subgroups except HFpEF baseline 0.87 (0.74–1.03); 0.11; 60%] no 0.92 (0.73–1.16); 0.50; 78%]. seemed have hypovolaemia, hyperkalaemia, hypotension when compared placebo. Conclusions HF, substantially increase outcomes, including all-cause mortality. this meta-analysis, did not show fraction (HFpEF) baseline.